Perceptronix Sponsors University of British Columbia Dentistry Research Day
Published: Jan 26, 2009
VANCOUVER, BRITISH COLUMBIA--(Marketwire - January 26, 2009) - Perceptronix is proud to be a silver sponsor for the 2009 UBC Dentistry Research Day on January 27 with its focus on early detection of oral cancer. This event closely parallels the company's agenda in promoting early cancer diagnosis for better patient outcomes. Perceptronix will be showcasing and demonstrating the use of OralAdvance™, a new quantitative cytology test for the early detection of oral cancer.
With recent advances in visualization techniques for the oral cavity, dentists are encountering more suspicious lesions. OralAdvance™, with its soft cyto-brush sample collection kit, provides dentists with an informative new option for assessing these lesions when biopsy is not warranted or possible. It provides an objective measure of gross DNA abnormality that can give important information about the pre-malignant or malignant nature of a lesion.
About Perceptronix Medical Inc.
Perceptronix Medical Inc. (Vancouver, Canada) is a private laboratory and cancer diagnostics company specializing in the provision of innovative early cancer detection tests based on quantitative cytology. The Company's DNA image cytometry technology was developed in partnership with the British Columbia Cancer Agency (Vancouver, Canada). Quantitative cytology provides physicians with an innovative cytopathology assessment based on an objective measure of large-scale DNA abnormality that can indicate precancerous or cancerous changes. The company has developed proprietary tests for the early detection of lung cancer and oral cancer using its DNA cytometry technology and offers quantitative cytology analysis of various tissues.
Perceptronix Medical Inc.
Alexei Doudkine, PhD
Director of Business Development